Elite Pharmaceuticals Initiates Pivotal Bioequivalence Study for ELI-201
July 15, 2014 10:31 ET
|
Elite Pharmaceuticals, Inc.
NORTHVALE, N.J., July 15, 2014 (GLOBE NEWSWIRE) -- Elite Pharmaceuticals, Inc. ("Elite" or the "Company") (OTCBB:ELTP) announced today the first dosing of a pivotal bioequivalence study in healthy...
Elite Pharmaceuticals Begins Human Abuse Liability Studies for ELI-200
June 09, 2014 08:00 ET
|
Elite Pharmaceuticals, Inc.
NORTHVALE, N.J., June 9, 2014 (GLOBE NEWSWIRE) -- Elite Pharmaceuticals, Inc. ("Elite" or the "Company") (OTCBB:ELTP) today announced dosing of the first subject in the treatment phase for a human...
Elite Pharmaceuticals Initiates Pivotal Bioequivalence Study for Third Opioid Abuse Deterrent Product
May 19, 2014 08:15 ET
|
Elite Pharmaceuticals, Inc.
NORTHVALE, N.J., May 19, 2014 (GLOBE NEWSWIRE) -- Elite Pharmaceuticals, Inc. ("Elite" or the "Company") ("Elite") (OTCBB:ELTP) announced today the first dosing of a pivotal bioequivalence study in...
Elite Pharmaceuticals Appoints Barbara Ellison as Vice President of Quality Operations and Regulatory Affairs
March 27, 2014 12:15 ET
|
Elite Pharmaceuticals, Inc.
NORTHVALE, N.J., March 27, 2014 (GLOBE NEWSWIRE) -- Elite Pharmaceuticals, Inc. ("Elite" or the "Company") (OTCBB:ELTP) today announced that it has created the position of Vice President, Quality...